Trial Profile
Role of rFVIIIFc (Eloctate) in Immune Tolerance Induction in children with severe hemophilia A and an anti-FVIII inhibitor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics
- 21 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology